

Spacers and Valved Holding Chambers—The Risk of Switching to Different Chambers



Federico Lavorini, MD, PhD^a, Celeste Barreto, MD^b, Job F.M. van Boven, PhD^c, Will Carroll, MD^d, Joy Conway, PhD^e, Richard W. Costello, MD^f, Birthe Hellqvist Dahl, PhD^g, Richard P.N. Dekhuijzen, MD^h, Stephen Holmes, MDⁱ, Mark Levy, MD^j, Mathieu Molimard, MD, PhD^k, Nicholas Roche, MD, PhD^l, Miguel Román-Rodríguez, MD^m, Nicola Scichilone, MDⁿ, Jane Scullion, MSc^o, and Omar S. Usmani, MD, PhD^p *Florence and Palermo, Italy; Lisbon, Portugal; Groningen and Nijmegen, The Netherlands; Stoke-On-Trent, Southampton, Somerset, London, and Leicester, United Kingdom; Dublin, Ireland; Aarhus, Denmark; Bordeaux and Paris, France; and Mallorca, Spain*

Spacers are pressurized metered-dose inhaler (pMDI) accessory devices developed to reduce problems of poor inhaler technique with pMDIs. Spacers that feature a 1-way inspiratory valve are termed valved holding chambers (VHCs); they act as aerosol reservoirs, allowing the user to actuate the pMDI device and then inhale the medication in a 2-step process that helps users overcome challenges in coordinating pMDI actuation with inhalation. Both spacers and VHCs have been shown to increase fine particle delivery to the lungs, decrease oropharyngeal

deposition, and reduce corticosteroid-related side effects such as throat irritation, dysphonia, and oral candidiasis commonly seen with the use of pMDIs alone. Spacers and VHCs are not all the same, and also are not interchangeable: the performance may vary according to their size, shape, material of manufacture and propensity to become electrostatically charged, their mode of interface with the patient, and the presence or otherwise of valves and feedback devices. Thus, pairing of a pMDI plus a spacer or a VHC should be considered as a unique delivery system. In this

^aDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy

^bDepartamento de Pediatria, Hospital de Santa Maria (CHLN), Centro Académico de Medicina de Lisboa, Lisbon, Portugal

^cUniversity of Groningen, University Medical Centre Groningen, Groningen Research Institute for Asthma and COPD, Department of General Practice and Elderly Care Medicine, Groningen, The Netherlands

^dDepartment of Paediatrics, University Hospital of North Midlands NHS Trust, Stoke-On-Trent, United Kingdom

^eComputationally Intensive Imaging, University of Southampton, Southampton, United Kingdom

^fDepartment of Respiratory Medicine, RCSI, Dublin, Ireland

^gDepartment of Respiratory Diseases & Allergy, Aarhus University Hospital, Aarhus, Denmark

^hRadboud University Medical Centre, Nijmegen, The Netherlands

ⁱPark Medical Practice, Shepton Mallet, Somerset, United Kingdom

^jHarrow Primary Care Trust, London, United Kingdom

^kDépartement de Pharmacologie, CHU de Bordeaux, Université Bordeaux, Bordeaux, France

^lRespiratory Medicine, Cochin Hospital APHP, University Paris Descartes, Paris, France

^mPrimary Care Respiratory Research Unit, Instituto de Investigación Sanitaria de las Islas Baleares, Mallorca, Spain

ⁿDepartment of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

^oUniversity Hospitals of Leicester, Leicester, United Kingdom

^pImperial College London & Royal Brompton Hospital, London, United Kingdom

Conflicts of interest: F. Lavorini reports personal fees and grants for research from AstraZeneca, Chiesi, GlaxoSmithKline (GSK), Menarini International, Novartis Pharmaceuticals, Orion Pharmaceuticals, and Trudell Medical International. J. F. M. van Boven reports personal fees, consultancy fees, and/or research grants from Boehringer Ingelheim, Menarini, Trudell Medical International, AstraZeneca, and GSK. W. Carroll reports personal fees from GSK, Novartis Pharmaceuticals, and Trudell Medical International and nonfinancial research support from GSK. J. Conway reports financial assistance and/or contracts from AstraZeneca, Algi-pharma, Air Liquide France, Pari GmbH, Novus, Fisher and Paykel, Breathe, and Trudell Medical International. R. W. Costello reports speaker fees from Boehringer Ingelheim, AstraZeneca, GSK, Teva, and Novartis; 2 patents on techniques related to adherence; and grant support from Aerogen and GSK. B. H. Dahl reports fees from Boehringer Ingelheim, AstraZeneca, Novartis, and Trudell Medical International. R. P. N. Dekhuijzen reports grants and personal fees from

Chiesi, AstraZeneca, Teva, Mundipharma, Boehringer Ingelheim, Trudell Medical International, Sandoz, and Zambon. S. Holmes reports personal fees from AstraZeneca, Beximco, Boehringer Ingelheim, Chiesi, GSK, Johnson and Johnson, Mylan, Napp, Novartis, Nutricia, Orion, Pfizer, Sandoz, Teva, and Trudell Medical International; fees from Bristol North Somerset and South Gloucester CCG, Heywood Middleton and Rochdale CCG, Rushcliffe CCG, Somerset CCG, Medicof, MIMS, Nursing in Practice, Pulse and RCGP conferences, and educational meetings. M. Levy reports personal fees, grants, and nonfinancial support from Chiesi, Clement Clarke International, Consorzio Futuro In Ricerca, Teva, AstraZeneca, Soar Beyond, Orion Pharmaceuticals, Napp Pharmaceuticals, National Services for Health Improvement, Novartis Pharmaceuticals, GSK, Trudell Medical International, GINA, and Asthma and COPD (Joint) Lead for Whole Systems Integrated Care (WSIC) NorthWest London. M. Molimard reports consulting fees from Boehringer Ingelheim, GSK, Novartis, and Trudell Medical International. N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis, and Pfizer and personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Cipla, Sanofi, Sandoz, 3M, and Zambon. M. Román-Rodríguez reports personal fees and grants from AstraZeneca, Boehringer Ingelheim, GSK, Mundipharma, Novartis, Teva, and Trudell Medical International. N. Scichilone reports grant and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Sanofi, and Trudell Medical International. J. Scullion reports personal fees from AstraZeneca, Boehringer Ingelheim, Mundipharma, Chiesi, Mylan, Napp, Novartis, Nutricia, Orion, Pfizer, Sandoz, Teva, Trudell Medical International, MIMS, Nursing in Practice, Consorzio Futuro In Ricerca, and Phillips. O. S. Usmani reports grants and/or personal fees from Trudell Medical International, AstraZeneca, Boehringer Ingelheim, Chiesi, Aerocrine, GSK, NAPP, Mundipharma, Sandoz, Takeda, Cipla, and Pearl Therapeutics outside the submitted work. C. Barreto reports no relevant conflict of interests.

Received for publication May 1, 2019; revised December 9, 2019; accepted for publication December 29, 2019.

Available online January 9, 2020.

Corresponding author: Federico Lavorini, MD, PhD, Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy. E-mail: federico.lavorini@unifi.it.

2213-2198

© 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.jaip.2019.12.035>

Abbreviations used

pMDI- Pressurized metered-dose inhaler

VHC- Valved holding chamber

Rostrum we discuss the risk potential for a patient getting switched to a spacer or VHC that delivers a reduced dose medication.

© 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). (J Allergy Clin Immunol Pract 2020;8:1569-73)

Key words: Spacer; Valved holding chamber; Inhalers

INTRODUCTION

Pressurized metered-dose inhalers (pMDIs) are the most widely used devices for delivery of aerosol medications due to their effectiveness and relative simplicity of use.¹ However, an important weakness of pMDIs is their propensity to be used sub-optimally or incorrectly,² a problem that has been recognized since their inception and that is unfortunately still present today.³ In a survey conducted among persons referred by family physicians, internists, surgeons, and pulmonologists for routine spirometry, only 10.8% of the subjects correctly performed all the maneuvers recommended for self-administration and 24.7% failed to perform more than half the maneuvers adequately.⁴ A review of 2123 patients with asthma by the National Services for Health Improvement found that, without training, 86% failed to properly use their inhaler.⁵ Even with inhaler training, some people will revert to bad technique, and some will not benefit from training.⁶ One of the most common errors associated with pMDIs is the lack of coordination between inhaler actuation and inhalation.² Coordination between inhalation and generation of the aerosol, so that the inhaler should be activated just after onset of inspiration, is crucial to increase drug deposition in the lung during pMDI use.⁷ In the CRITIKAL study, poor coordination between inhaler activation and inhalation led to a greater likelihood of uncontrolled asthma symptoms and a higher rate of exacerbations.⁸

Spacers and valved holding chambers (VHCs) are medical devices, made of either polycarbonate plastics or metal, that interface with the pMDI. They are shaped like a tube with openings at both ends: one opening is the mouthpiece that is placed into the mouth (or a facemask fitting the spacer with a tight seal) and the other opening is where the pMDI is inserted.⁹⁻¹¹ In this way, they provide additional space for the aerosol plume to develop.⁹⁻¹¹ In fact, with either a spacer or a VHC, the aerosol flows from the pMDI into the chamber, thus allowing deceleration of the aerosol plume and, in the case of VHCs, trap the aerosol cloud until the patient inhales from the chamber rather than directly from the pMDI.⁹⁻¹¹ This greatly reduces oropharyngeal drug deposition via retention of large aerosol particles within the holding chamber, thus reducing the potential for corticosteroid-related local side effects (ie, candidiasis and dysphonia) and systemic absorption.⁹⁻¹¹ Although the terms “spacer” and “VHC” are frequently used interchangeably, the former is a generic term for any open tube, sometimes made from household items such as toilet paper rolls or plastic soda

bottles,^{12,13} placed on the mouthpiece of the pMDI to extend its distance from the patient’s mouth.⁹⁻¹¹ However, a VHC is a spacer that is manufactured with a 1-way, low-resistance valve to regulate inspiratory flow and prevent exhalation into the device.⁹⁻¹¹ The newer VHCs such as the AerochamberFlow-Vu (Trudell Medical International, London, Ontario, Canada), the Opti-Chamber Diamond (Philips Respironics, Guildford, Surrey, UK), or the InspiraChamber (Lupin Pharmaceuticals, Pune, Maharashtra, India) have an alert whistle to provide feedback on correct inspiratory flow.¹⁴ The VHCs are generally preferable to simple spacers because the latter, because of the lack of a 1-way valve, are susceptible to dispersal of the aerosol within due to uncoordinated exhalation into the chamber. In addition, VHCs substantially lessen the need of inhaler actuation-inhalation coordination, which is problematic for both adults^{1,2} and children.¹⁵ As a result, VHCs may increase pulmonary deposition of drug suspensions¹⁶ and, compared with the pMDI alone, may improve clinical outcomes including airway hyper-responsiveness,¹⁷ lung function,¹⁸⁻²⁰ and asthma control,²¹ with a reduction in the requirement for oral corticosteroids.²² Accordingly, the use of VHCs is firmly recommended in international guidelines on the management of asthma²³⁻²⁵ and chronic obstructive pulmonary disease²⁶ (Table I), particularly in patients prone to pMDI handling errors.²⁷ Although patients who have correct technique with pMDIs may not derive any benefit from the use of VHCs,²⁷ the latter reduce oropharyngeal deposition of large aerosol particles emitted from a pMDI, even with “perfect” technique.²⁸

Although the potential benefits of spacers/VHCs are clear, there is less consensus as to whether there are any meaningful differences between different devices. There is substantial, occasionally contradictory, literature detailing the relative performance of a large number of different spacers or VHCs.²⁹ It is well established from *in vitro* studies that a specific VHC may perform differently with different drugs³⁰⁻³² or a specific drug may perform differently in terms of emitted fine particle mass if inhaled through different VHCs.³³ Thus, substitution of one type of spacer or VHC with another may have both safety and clinical implications unless otherwise proven as equivalent through *in vitro* and/or *in vivo* studies. Hatley et al³⁴ found that the aerodynamic particle size distribution of albuterol aerosols obtained by 2 antistatic VHCs was similar but significantly different from that obtained by using a conventional VHC. Recently, D’Vaz et al³⁵ reported no difference in the bronchodilator response, as assessed by FEV₁ changes, to salbutamol inhaled through different spacers in children with asthma.³⁵ Accordingly, radiolabeled aerosol studies found equivalent lung deposition of aerosol using different spacers.³⁶ However, detection of differences in the bronchodilator response to an agent delivered by different devices may be difficult due to the potentially confounding effects related to the patient inhalation technique, as well as due to the variability in the levels of airway narrowing, especially when such variability is not adequately accounted for in patient selection.^{18,19} In addition, even low doses of bronchodilators delivered by virtually any inhalation device may produce near-maximal bronchodilator responses falling on the flat part of the dose-response curve.^{18,19,37} Although some studies failed to show significant differences in lung deposition between different spacers/VHCs,³⁶ others found that large-volume (≥ 750 mL) resulted in greater whole lung deposition compared with smaller devices.³⁸ Differences in the

TABLE I. Guidelines recommending spacer or VHCs

Institution	Year	Recommendation(s)
American Association of Respiratory Care	2007	A spacer/VHC should be used with an MDI; a spacer/VHC with facemask is appropriate for patients (usually < 3 y) unable to use a mouthpiece.
American College of Chest Physicians/American College of Allergy, Asthma & Immunology	2005	For patients who have trouble coordinating inhalation with device actuation, the use of a spacer (with a valve) may obviate this difficulty; the use of spacers is mandatory for infants and young children.
British Thoracic Society/Scottish Intercollegiate Guidelines Network	2012	Children and adults with mild and moderate exacerbations of asthma should be treated by bronchodilators given from a pMDI + spacer/VHC, with doses titrated according to clinical response; in children aged 0-5 y, pMDI + spacer are the preferred method of delivery of β_2 agonists or inhaled steroids; the spacer should be compatible with the pMDI being used.
Canadian Pediatric Asthma Consensus Guidelines	2005	The use of a VHC with pMDI is strongly recommended for children.
Canadian Thoracic Society	2010	The addition of a VHC with mouthpiece is helpful in overcoming poor hand-mouth coordination and reducing side effects, with increased drug delivery and lung deposition; VHCs with facemask attachments are useful for the elderly, who can use 4-6 tidal breaths for each actuation of the medicine.
Global Initiative for Asthma	2017	pMDI + dedicated spacer/VHC with facemask is the preferred delivery system for children aged 4 y and younger; pMDI + dedicated spacer/VHC with mouthpiece is the preferred delivery system for children aged between 4 and 6 y.
Global Initiative for Chronic Obstructive Lung Disease	2014	For the MDI, the addition of a large- or small-volume spacer often overcomes coordination problems, and improves lower airway deposition and clinical benefit.
International Primary Care Respiratory Group	2006	The preferred device for administering inhaled asthma medication for infants and young children is a pMDI with a spacer and face mask; as the child's ability to co-operate improves (often around the age of 4-6 y), a spacer with a mouthpiece can be used rather than a facemask.
National Heart, Lung, and Blood Institute	2007	All patients taking inhaled steroids should use a spacer/VHC; patients younger than 5 y should use a spacer/VHC with facemask for inhaled steroids.
Dutch College of General Practitioners (NHG) guidelines asthma and COPD	2014	Children: pMDIs should always be used in combination with a spacer/VHC. Adults: pMDIs should always be used in combination with a spacer/VHC, unless the patient can use a pMDI adequately.
National Institute for Clinical Excellence (UK)	2010	Spacer/VHC recommended with a facemask where necessary for both corticosteroids and bronchodilators (children younger than 5 y); a pMDI used with an appropriate spacer/VHC is first choice for corticosteroids (children aged 5-15 y); for patients with chronic obstructive pulmonary disease, pMDI alone is rarely suitable for use with the elderly; the spacer should be compatible with the patient's pMDI.

study design and methodology may account for these contradictory results.

Dissanayake et al³⁹ set out to address the impact of spacer design on drug delivery performance and look at potential implications for clinical use. Four similarly sized chambers were compared “out of the box” in terms of statistical equivalence with the most widely prescribed, nonconducting VHC, Aerochamber Plus chamber (Trudell Medical International) with respect to retention of drug particles within the device and the aerodynamic particle size distribution of the drug particles delivered. The authors found that only the Aerochamber Flow-Vu chamber demonstrated an equivalent profile of dose retention and delivery versus the reference chamber. The Compact Space Chamber Plus (Medical Developments, Victoria, Australia), the OptiChamber Diamond, and InspiraChamber devices all retained approximately twice as much drug, delivering around half the dose and showing nonequivalent performance compared with the Aerochamber Flow-Vu chamber and the reference chamber (pretreated AerochamberPlus chamber). Thus, the performance of VHCs that resemble one another in terms of appearances and dimensions may differ markedly, implying that VHCs should not automatically be considered interchangeable.³⁹ Although equivalent performance

between different VHCs has been demonstrated,³⁴ a recent *in vitro* study⁴⁰ and a literature review¹⁴ provide further support for the results found by Dissanayake et al.³⁹ In considering the important attributes of such delivery devices, the review notes a shift in emphasis from chamber size and shape to other aspects, such as consistency of drug delivery, static charge reduction, valve performance, and factors optimizing facemask effectiveness, such as flexibility and seal.¹⁴ Because differences exist between different spacers or different VHCs, which in some cases are sufficiently large that meaningful and overt clinical differences would be anticipated as a result, each pMDI spacer/VHC combination should be treated as a unique inhaled medication delivery system.²⁹ In this connection, the European Medicines Agency guidance recommends that the development and registration process for drug products delivered by pMDIs include testing and supporting *in vitro* and *in vivo* data of the pMDI when used with at least 1 named spacer/VHC.⁴¹ In addition, the European Medicines Agency guidance states that patients with asthma with well-controlled disease by inhaled medications delivered through pMDIs plus spacer/VHC should always use the same type of spacer/VHC and not switch to a different spacer/VHC that may deliver different amounts of drugs.⁴¹

The European Union registration documentation for pMDIs (Summary of Product Characteristics and Patient Information Leaflet) specifically notes that the VHC to be used should be based on the device used in the product development/registration studies. In case of a spacer/VHC substitution, appropriate equivalency data for the alternative device must be presented.⁴¹ Surprisingly, at variance with European Medicines Agency, other regulatory authorities, such as for instance the US Food and Drug Administration, do not require data for a specific named spacer to support pMDI approval. However, in a draft Food and Drug Administration Chemistry, Materials and Controls Industry guidance for orally inhaled products issued in 1998 by the Center for Drug Evaluation and Research, there is recognition that clinical efficacy assessment of pMDI-delivered aerosols requires consideration of the presence of a spacer/VHC.⁴²

CONCLUSIONS

There is published evidence that the union of a particular pMDI and a given spacer/VHC is considered a specific inhaled medication delivery system. Therefore, we recommend physicians to focus on selecting the most appropriate spacer/VHC for the patient and their pMDI(s), given the weight of clinical evidence available. Although the noninterchangeability of VHCs is recognized,^{14,34,40} we also recommend clinicians to monitor for any changes in disease control if the patient's VHC was switched. Furthermore, we believe that pharmacists need to appreciate that spacers/VHCs may deliver different amounts of drug from the pMDI and therefore substitution of a different device from that prescribed by the physician may have an impact on the patient. Finally, regulatory authorities need to be aware of the risks inherent in the current approval process of spacer VHCs through CE mark registration and look for improvements to, at the very least, restrict the ability of devices with serious design/quality flaws to be approved and used by patients.

REFERENCES

- Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. *Chest* 2005;127:335-71.
- Lavorini F. The challenge of delivering therapeutic aerosols to asthma patients. *ISRN Allergy* 2013;102418.
- Sanchis J, Gich I, Pedersen S. Systemic review of errors in inhaler use: has patient technique improved over time? *Chest* 2016;150:394-406.
- Epstein SW, Manning CPR, Ashley MJ, Corey PN. Survey of the clinical use of pressurized aerosol inhalers. *Can Med Assoc J* 1979;120:813-6.
- Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy ML. Technique training does not improve the ability of most patients to use pressurized metered-dose inhalers (pMDIs). *Prim Care Respir J* 2011;20:92-6.
- McFadden ER Jr. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. *J Allergy Clin Immunol* 1995;96:278-83.
- Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. *Eur J Resp Dis* 1982;63:57-65.
- Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. *J Allergy Clin Immunol Pract* 2017;5:1071-81.
- Lavorini F, Fontana GA. Targeting drugs to the airways: the role of spacer devices. *Expert Opin Drug Deliv* 2009;6:91-102.
- Nikander K, Nicholls C, Denyer J, Pritchard J. The evolution of spacers and valved holding chambers. *J Aerosol Med Pulm Drug Deliv* 2014;27:S4-23.
- Levy ML, Dekhuijzen PNR, Barnes PJ, Broeders M, Corrigan CJ, Chawes BL, et al. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). *Prim Care Respir Med* 2016;26:16017.
- Sanders M, Bruin R. A rationale for going back to the future: use of disposable spacers for pressurized metered dose inhalers. *Pulm Med* 2015;2015:176194.
- Zar HJ, Streu S, Levin M, Weinberg EG, Swingle GH. Randomised controlled trial of the efficacy of a metered-dose inhaler with bottle spacer for bronchodilator treatment in acute lower airway obstruction. *Arch Dis Child* 2007;92:142-6.
- Dissanayake S, Suggett J. A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamberPlus Flow-Vu Antistatic VHC. *Ther Adv Respir Dis* 2018;12. 1753465817751346.
- Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhaler. *Respir Care* 2005;50:1191-2000.
- Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. *Thorax* 1994;49:549-53.
- Broeders ME, Molema J, Hop WC, Folgering HT. Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI. *Eur J Clin Pharmacol* 2005;60:837-41.
- Lavorini F, Geri P, Luperini M, Maluccio NM, Mariani L, Marmai C, et al. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction. *Br J Clin Pharmacol* 2004;58:512-20.
- Lavorini F, Geri P, Mariani L, Marmai C, Maluccio NM, Pistolesi M, et al. Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism. *Br J Clin Pharmacol* 2006;62:403-11.
- Lavorini F, Geri P, Camiciottoli G, Pistolesi M, Fontana GA. Agreement between two methods for assessing bioequivalence of inhaled salbutamol. *Pulm Pharmacol Ther* 2008;21:380-4.
- Levy ML, Hardwell A, McKnight E, Holmes J. Asthma patients' inability to use a pressurized metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the Global Initiative for Asthma (GINA) strategy: a retrospective analysis. *Prim Care Respir J* 2013;22:406-11.
- Salzman GA, Pyszczynski DR. Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with AeroChamber. *J Allergy Clin Immunol* 1988;81:424-8.
- The Global Initiative for Asthma (GINA) 2018. Available from: <https://ginasthma.org/>. Accessed June 1, 2019.
- British Thoracic Society/Scottish Intercollegiate Guidance Network (SIGN). British guideline on the management of asthma. Publication 63. 2005. Available from: <http://www.sign.ac.uk>. Accessed July 1, 2019.
- UK National Institute for Clinical Excellence. Guidance on the use of inhaler systems (devices) in children under the age of 5 with chronic asthma. Technology appraisal guidance No. 10. Available from: <http://www.nice.org.uk>.
- Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: <https://goldcopd.org>. Accessed November 20, 2018.
- Lee H, Evans HE. Evaluation of inhalation aids of metered dose inhalers in asthmatic children. *Chest* 1987;91:366-9.
- Newman SP, Woodman G, Clarke SW, Sackner MA. Effect of InspirEase on the deposition of metered-dose aerosols in the human respiratory tract. *Chest* 1986;89:551-6.
- Mitchell J, Dolovich MB. Clinically relevant test methods to establish in vitro equivalence for spacers and valved holding chambers used with pressurized metered dose inhalers (pMDIs). *J Aerosol Med Pulm Drug Deliv* 2012;25:217-42.
- Dubus JC, Rhem R, Dolovich M. Delivery of HFA and CFC salbutamol from spacer devices used in infancy. *Int J Pharm* 2001;222:101-8.
- Ahrens R, Lux C, Bahl T, Han S. Choosing the metered dose inhaler spacer or holding chamber that matches the patient's need: evidence that specific drug being delivered is an important consideration. *J Allergy Clin Immunol* 1995;96:288-94.
- Barry PW, O'Callaghan C. A comparative analysis of the particle size output of beclomethasone dipropionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the Babyhaler, Volumatic and AeroChamber spacer devices. *Br J Clin Pharmacol* 1999;47:357-60.
- Barry PW, O'Callaghan C. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. *Eur Respir J* 1997;10:1345-8.
- Hatley RH, von Hollen D, Sandell D, Slatore L. In vitro characterization of the OptiChamber Diamond valved holding chamber. *J Aerosol Med Pulm Drug Deliv* 2014;27:S24-36.

35. D'Vaz N, Okitika TA, Shackleton C, Devadason SG, Hall GL. Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection. *Pediatr Pulmonol* 2019;54:531-6.
36. Zar HJ, Weinberg EG, Binns HJ, Gallie F, Mann MD. Lung deposition of aerosol—a comparison of different spacers. *Arch Dis Child* 2000;82:495-8.
37. Prabhakaran S, Shuster J, Arhens R, Hendeles L. Methacholine challenge as a clinical bioassay of pulmonary delivery of a long-acting β_2 -adrenergic agonist. *Pharmacotherapy* 2011;31:449-57.
38. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. *J Aerosol Med* 1996;9:55-70.
39. Dissanayake S, Nagel M, Falaschetti E, Suggett J. Are valved holding chambers (VHCs) interchangeable? An in vitro evaluation of VHC equivalence. *Pulm Pharmacol Ther* 2018;48:179-84.
40. Hagedoorn P, Bawary W, Frijlink HW, Grasmeijer F. A comparative analysis of changes in pMDI drug dose delivery before and after detergent coating using five antistatic valved holding chambers. *J Allergy Clin Immunol Pract* 2020;8:1124-1125.e4.
41. European Medicines Agency. Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. CPMP/EWP/4151/00 Rev. 1. London: European Medicines Agency; 2009.
42. US Federal Drug Administration. Draft guidance: metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing and controls documentation. Docket 98D-0997. Rockville, MD: Center for Drug Evaluation and Research. Available from: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070573.pdf>. Accessed September 21, 2011.